Tamoxi20 mg

Tamoxi is a nonsteroidal selective estrogen receptor modulator (SERM) indicated in the following settings:

Established / FDA-approved uses

• Adjuvant treatment of breast cancer: Tamoxi is indicated for adjuvant treatment of hormone receptor-positive breast cancer in women, including in node-positive disease following surgery/radiation, to reduce the risk of recurrence.
• Metastatic breast cancer: Tamoxi is indicated for the treatment of hormone receptor-positive metastatic breast cancer in women and in men.
• Reduction of contralateral breast cancer: Tamoxi is indicated to reduce the incidence of a new cancer in the opposite breast in women receiving treatment for breast cancer.
• Reduction of breast cancer risk in high-risk women (chemoprevention): Tamoxi is indicated to reduce the incidence of invasive breast cancer in women at high risk, based on age, family history, prior biopsy findings, and other validated risk-assessment tools.
• Ductal carcinoma in situ (DCIS): Tamoxi is indicated to reduce the risk of invasive breast cancer in women with DCIS, following surgery and radiation, to reduce the risk of a subsequent breast cancer.

Off-label use (not FDA-approved)

• Ovulation induction: Tamoxi is used off-label in some fertility settings, generally when standard agents are unsuitable or unavailable; this use requires specialist supervision and is not an approved indication.
• Gynecomastia and mastalgia: Tamoxi is sometimes used off-label for painful gynecomastia or mastalgia under specialist care.

The balance of benefit and serious risk (see Precautions and Warnings) differs substantially between treatment of existing cancer and use for risk reduction in otherwise healthy women, and this should be discussed individually with a physician.

Each tablet contains Tamoxifen Citrate equivalent to a stated amount of tamoxifen base, commonly available in strengths such as 10 mg and 20 mg. Tablets also contain standard pharmaceutical excipients (e.g., lactose, microcrystalline cellulose, starch, magnesium stearate). Exact strengths and excipients vary by manufacturer; refer to the specific marketed product label for the formulation of Tamoxifen Citrate being dispensed.

Tamoxi is the citrate salt of tamoxifen, a nonsteroidal selective estrogen receptor modulator (SERM) used primarily in the management of hormone receptor-positive breast cancer. It acts as an estrogen antagonist in breast tissue while exhibiting partial estrogen-agonist activity in other tissues such as the endometrium and bone, which underlies both its therapeutic benefit and some of its serious risks.

Tamoxi is administered orally as tablets and is used under oncology or gynecologic-oncology supervision for treatment of existing breast cancer, prevention of a second breast cancer, or reduction of breast cancer risk in high-risk women, always with individualized assessment of risks such as uterine cancer and thromboembolic disease.

Tamoxi belongs to the class of Selective Estrogen Receptor Modulators (SERMs), also broadly classified as an antineoplastic hormonal / antiestrogen agent used in oncology and gynecologic practice.

Tamoxifen Citrate competitively binds to estrogen receptors on tumor and other target tissues, forming a nuclear complex that decreases DNA synthesis and inhibits estrogen-mediated cellular effects. Its action is tissue-selective: it behaves as an estrogen-receptor antagonist in breast tissue (reducing growth stimulation of hormone receptor-positive breast cancer cells) but as a partial agonist in the endometrium and bone, which explains its beneficial effect on bone density but also its association with endometrial proliferation and cancer risk.

Tamoxifen Citrate is extensively metabolized in the liver, primarily via CYP3A4 and CYP2D6, to several active metabolites, including 4-hydroxytamoxifen and endoxifen, which have substantially greater affinity for the estrogen receptor than the parent compound and are thought to contribute significantly to overall clinical efficacy. This means drugs that inhibit CYP2D6 can meaningfully reduce the formation of active metabolite and potentially reduce effectiveness (see Drug Interactions).

Tamoxi tablets are administered orally, with or without food, swallowed whole with a glass of water. Doses given more than once daily should be spaced evenly (e.g., morning and evening). Tamoxi should be taken exactly as prescribed and not stopped or altered without consulting the prescribing physician, given its role in long-term cancer treatment or risk reduction.

Tamoxi has several clinically significant drug interactions:

• Warfarin and other coumarin-type anticoagulants: Tamoxi can potentiate the anticoagulant effect, increasing bleeding risk. Concurrent use is contraindicated in women receiving Tamoxi for reduction of breast cancer risk or for DCIS; in women being treated for active breast cancer, concurrent use requires close INR monitoring and dose adjustment of the anticoagulant under specialist supervision.
• CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, bupropion, quinidine, cinacalcet): these can significantly reduce conversion of Tamoxi to its active metabolite endoxifen, potentially reducing anti-cancer effectiveness. Strong CYP2D6 inhibitors should generally be avoided during Tamoxi therapy; if an antidepressant is needed for hot flashes, agents with minimal CYP2D6 inhibition (e.g., venlafaxine, low-dose citalopram/escitalopram) are generally preferred, per physician judgment.
• Rifampin and other strong CYP3A4/CYP2D6 inducers: these can reduce plasma levels of Tamoxi and its active metabolites, potentially reducing efficacy.
• Estrogen-containing therapies (e.g., hormonal contraceptives, hormone replacement therapy): these may counteract the antiestrogenic action of Tamoxi and are generally avoided during treatment.

Patients should inform their physician of all prescription and over-the-counter medicines, including antidepressants, taken alongside Tamoxi.

Serious risks (boxed-warning level) associated with Tamoxi include:

• Uterine malignancies: increased risk of endometrial cancer and uterine sarcoma, particularly with long-term use; patients should promptly report any abnormal vaginal bleeding, spotting, or discharge.
• Stroke: increased risk, particularly in postmenopausal women, especially those using Tamoxi for risk reduction.
• Pulmonary embolism and deep vein thrombosis: increased risk of blood clots, which can be serious or life-threatening.

These serious risks must be weighed individually against the benefit of Tamoxi, which differs between women being treated for existing breast cancer and healthy high-risk women taking it for prevention.

Common side effects

• Hot flashes and flushing
• Night sweats
• Vaginal discharge, dryness, or itching
• Menstrual irregularities or amenorrhea
• Nausea
• Fluid retention/mild swelling
• Mood changes, irritability, or depressed mood
• Fatigue and headache
• Weight change and mild hair thinning

Less common but important side effects

• Ocular changes with long-term use, including cataracts and, rarely, retinopathy or corneal changes
• Hepatic effects, including rare fatty liver changes or abnormal liver enzymes
• Hypercalcemia and tumor flare (transient increase in bone pain or tumor-site symptoms) shortly after starting treatment in patients with bone metastases
• Rare severe skin reactions

Patients should seek urgent medical attention for leg swelling/pain, sudden breathlessness, chest pain, sudden vision changes, one-sided weakness, or abnormal vaginal bleeding while on Tamoxi.

Tamoxi is contraindicated during pregnancy because of the potential for fetal harm based on its mechanism of action and animal reproduction data. Women of childbearing potential should use effective, reliable non-hormonal contraception during treatment with Tamoxi and for a period after stopping treatment, as advised by their physician, because Tamoxi can also affect ovulation and may itself have hormonal effects on a developing fetus. Any suspected pregnancy during treatment should be reported to the prescribing physician immediately.

Tamoxi is generally advised to be avoided during breastfeeding, as it is unknown whether it is expressed in significant amounts in human milk and animal data raise concern for adverse effects in a nursing infant; a physician should be consulted to weigh alternatives before breastfeeding while on Tamoxi.

Tamoxi carries serious, well-established risks that require careful discussion between physician and patient before and during treatment (see Side Effects for full detail on uterine cancer, stroke, and blood clot risk). Key precautions include:

• Regular gynecologic follow-up is recommended, and any abnormal vaginal bleeding, spotting, or pelvic pain/pressure should be reported promptly, given the increased risk of endometrial changes and cancer.
• Patients with a personal history of thromboembolic disease should discuss the added risk with Tamoxi with their physician before starting therapy.
• Baseline and periodic eye examinations may be recommended for patients on long-term therapy, given the association with cataracts and, rarely, retinopathy.
• Caution is advised in patients with hepatic impairment given hepatic metabolism of Tamoxi, and periodic liver function monitoring may be recommended.
• Patients with pre-existing hypertriglyceridemia should have lipids monitored, as Tamoxi can occasionally cause marked elevations in triglycerides.
• In patients with bone metastases, monitoring for tumor flare and hypercalcemia is recommended shortly after starting Tamoxi.

Tamoxi should be taken exactly as prescribed by the physician; treatment should not be stopped, doses skipped, or the medicine shared with others without medical advice, since abrupt discontinuation may affect cancer treatment outcomes.

There is limited clinical experience with acute overdose of Tamoxi. Reported effects in overdose have generally been an extension of known pharmacological actions. Any suspected overdose of Tamoxi should be treated as a medical emergency — seek immediate medical attention, contact a poison control center, or go to the nearest emergency department. Do not attempt to manage a suspected overdose at home; treatment is supportive and should be directed by medical professionals.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Pregnancy

Tamoxi is contraindicated in pregnancy; effective non-hormonal contraception is required during treatment (see Pregnancy and Lactation).

Lactation

Tamoxi should generally be avoided during breastfeeding; consult a physician regarding alternatives (see Pregnancy and Lactation).

Pediatric use

Safety and efficacy of Tamoxi have not been established in children, as breast cancer is not a pediatric disease; use in pediatric patients is limited to rare specialist-directed off-label settings and is not routinely recommended.

Geriatric use

Tamoxi has been widely used in older women with breast cancer; no specific dose adjustment based on age alone is required, but elderly patients may be at higher baseline risk of stroke and thromboembolic events, so individual risk-benefit assessment is advised.

Hepatic impairment

Use with caution, as Tamoxi is extensively metabolized by the liver; no formal validated dose-adjustment schedule exists, so clinical monitoring is advised.

Renal impairment

No well-established dose adjustment is required for renal impairment, though clinical judgment should be used in patients with significant renal disease.

Duration of Tamoxi therapy is indication-specific and determined by the treating physician. For adjuvant breast cancer treatment, a course of 5 years is standard, with extension to 10 years considered in selected patients based on individual recurrence risk and tolerance, per current oncology guidance. For breast cancer risk reduction and DCIS, a 5-year course is typical. For metastatic disease, Tamoxi is generally continued until disease progression or unacceptable toxicity. Patients should not stop Tamoxi early without medical advice, as this can affect treatment outcomes.

Tamoxifen Citrate is classified as a Selective Estrogen Receptor Modulator (SERM), within the broader category of hormonal antineoplastic / antiestrogen agents used in oncology.

Tamoxifen Citrate exerts a tissue-selective effect on estrogen receptors: it competitively blocks estrogen from binding to its receptor in breast tissue, forming a receptor complex with reduced transcriptional activity that slows growth of hormone receptor-positive breast cancer cells, while acting as a partial estrogen-receptor agonist in the endometrium and bone. Its active metabolites, particularly endoxifen, have substantially higher receptor affinity than the parent compound and are largely responsible for its clinical antiestrogenic effect in breast tissue.

D

Tamoxi is not indicated for use in children, as the conditions it treats (hormone receptor-positive breast cancer, breast cancer risk reduction) are essentially adult diseases. Safety and efficacy of Tamoxi in pediatric patients have not been established, and its use in pediatric patients should be restricted to rare, specialist-directed circumstances outside its standard labeling, with careful discussion of risks and benefits with a pediatric specialist.